Top 10 healthcare ETFs to watch in 2026

By Stake Desk10 min read

You know these companies by the pharmacy counter and the hospital ward. Drug approvals and clinical trial results can move their share prices sharply.

Healthcare ETFs hold shares in companies that research, manufacture and deliver medical products and services – from pharmaceutical giants and hospital operators to biotech firms working on gene therapies. The ten funds on this list all focus on that sector, though they cut it differently: most track broad U.S. healthcare indices, while iShares Global Healthcare ETF ($IXJ) pulls in companies from outside the U.S. as well, and ARK Genomic Revolution ETF ($ARKG) takes an active approach focused on genomics and life sciences. Management costs range from 0.08% for State Street Health Care Select Sector SPDR ETF ($XLV) and Fidelity MSCI Health Care Index ETF ($FHLC) up to 0.75% for $ARKG.

How we built this list: We selected these funds based on their investment category and relevance to the theme, then ordered them by assets under management. Prices are updated daily, and the list and supporting content are reviewed roughly every quarter. All data is sourced from Stake. This list isn't a recommendation and isn't ordered by suitability.

ETF Name

Ticker

Share Price

AUM

Expense Ratio

In Watchlists

State Street Health Care Select Sector SPDR ETF

XLV

$177.24

$46.92B

0.08%

1543

Vanguard Health Care ETF

VHT

$326.69

$20.80B

0.09%

1403

iShares Biotechnology ETF

IBB

$199.54

$10.79B

0.44%

947

State Street SPDR S&P Biotech ETF

XBI

$140.18

$9.64B

0.35%

1144

iShares US Healthcare ETF

IYH

$74.08

$4.55B

0.37%

176

iShares Global Healthcare ETF

IXJ

$108.13

$4.49B

0.38%

410

Fidelity MSCI Health Care Index ETF

FHLC

$84.43

$3.90B

0.08%

130

ARK Genomic Revolution ETF

ARKG

$38.00

$1.72B

0.75%

7867

VanEck Pharmaceutical ETF

PPH

$114.85

$1.02B

0.35%

180

Invesco S&P 500 Eql Wght Health Care ETF

RSPH

$38.75

$1.21B

0.40%

76

Past performance is not a reliable indicator of future performance.

Source: Stake market data. Figures in US$. Data updated as of 20 November 2026.

✅ Learn more: Top ASX healthcare stocks to watch in 2026→

Looking to invest in Healthcare ETFs?

Sign up in minutes and get access to a CHESS-sponsored platform, where you can explore Healthcare ETFs and more.

1. State Street Health Care Select Sector SPDR ETF ($XLV)

XLV 1-year price chart: up 17.1%, from US$151.42 to US$177.24. Range US$142.84 to US$189.66.

Price: US$177.24 · Daily: -0.1% · AUM: US$46.92B · MER: 0.08%

State Street Health Care Select Sector SPDR ETF ($XLV) is designed to track the Health Care Select Sector Index, which covers the healthcare companies within the S&P 500. The fund aims to match that benchmark's price and yield performance before expenses. Under normal market conditions, $XLV targets at least 95% of its total assets in the index's constituent securities.

That high allocation floor keeps the fund closely tethered to its benchmark rather than accumulating cash on the side. Because the portfolio mirrors a defined index, its composition changes when the index itself rebalances.

2. Vanguard Health Care ETF ($VHT)

VHT 1-year price chart: up 15.9%, from US$281.77 to US$326.69. Range US$265.36 to US$351.23.

Price: US$326.69 · Daily: -0.4% · AUM: US$20.80B · MER: 0.09%

Vanguard Health Care ETF ($VHT) is designed to track the MSCI U.S. Investable Market Health Care Index, a benchmark covering U.S. companies in the health care sector. What sets it apart from narrower funds is the size range it pulls in: large-, mid- and small-cap companies all sit within its scope, not just the household-name pharmaceutical and insurance groups.

That breadth means $VHT aims to capture the health care sector across its full market structure – from established drugmakers down to smaller players working earlier in the pipeline. The index is U.S.-focused, so the fund's exposure stays domestic rather than reaching into international health care markets.

3. iShares Biotechnology ETF ($IBB)

IBB 1-year price chart: up 21.5%, from US$164.24 to US$199.54. Range US$160.41 to US$221.13.

Price: US$199.54 · Daily: -2.1% · AUM: US$10.79B · MER: 0.44%

The iShares Biotechnology ETF ($IBB) aims to track the ICE Biotechnology Index, which measures US-listed companies classified within the Biotechnology sub-industry. That means the portfolio focuses on a single corner of healthcare – firms working on biological medicines, gene-based treatments and related research – rather than spreading across the broader sector.

The fund is designed to invest at least 90% of its assets in the securities that make up the underlying index, keeping its exposure tightly aligned to that benchmark. Biotechnology companies tend to carry meaningful research and regulatory risk, so the fund's performance can move sharply around clinical trial results or drug approval decisions.

4. State Street SPDR S&P Biotech ETF ($XBI)

XBI 1-year price chart: up 23.1%, from US$113.83 to US$140.18. Range US$113.83 to US$169.55.

Price: US$140.18 · Daily: -2.7% · AUM: US$9.64B · MER: 0.35%

State Street SPDR S&P Biotech ETF ($XBI) aims to replicate the performance of the S&P Biotechnology Select Industry Index, which draws from the biotechnology segment of a broad U.S. total market composite index. The fund uses a passive management strategy to do that, rather than active stock selection.

The S&P Biotechnology Select Industry Index uses an equal-weight construction, so smaller biotech companies carry similar weight to the larger names in the index. That means $XBI's return profile can look quite different from a market-cap-weighted biotech fund, where the biggest companies dominate.

5. iShares US Healthcare ETF ($IYH)

IYH 1-year price chart: up 16.3%, from US$63.72 to US$74.08. Range US$59.98 to US$79.85.

Price: US$74.08 · Daily: -0.3% · AUM: US$4.55B · MER: 0.37%

iShares US Healthcare ETF ($IYH) aims to track the Russell 1000 Health Care RIC 22.5/45 Capped Index, which measures the healthcare sector within the Russell 1000 universe of U.S. equities. The capping structure in the index name refers to concentration limits – designed to prevent any single holding from dominating the portfolio.

The fund is intended to hold the component securities of that index directly. Its focus is U.S. healthcare companies broadly, covering the range of businesses that make up the sector rather than a narrower slice of it.

Join 1M+ on Stake

Effortless investing in U.S. shares & ETFs

6. iShares Global Healthcare ETF ($IXJ)

IXJ 1-year price chart: up 14.0%, from US$94.88 to US$108.13. Range US$90.75 to US$115.53.

Price: US$108.13 · Daily: -0.5% · AUM: US$4.49B · MER: 0.38%

iShares Global Healthcare ETF ($IXJ) aims to match the performance of the S&P Global Healthcare Sector Index, which draws from the broader S&P Global 1200 Index. Standard & Poor's selects companies it considers part of the healthcare sector and important to global markets, so the index reaches beyond the U.S. to include healthcare names across multiple countries.

That global reach sets $IXJ apart from the U.S.-focused funds elsewhere in this article. The trade-off is that the portfolio reflects Standard & Poor's own definition of which companies qualify as globally significant, rather than simply capturing every listed healthcare name worldwide.

7. Fidelity MSCI Health Care Index ETF ($FHLC)

FHLC 1-year price chart: up 16.3%, from US$72.59 to US$84.43. Range US$68.53 to US$90.77.

Price: US$84.43 · Daily: -0.4% · AUM: US$3.90B · MER: 0.08%

Fidelity MSCI Health Care Index ETF ($FHLC) is designed to track the MSCI USA IMI Health Care Index, a benchmark that covers the health care sector across the U.S. equity market. At least 80% of the fund's assets are held in securities drawn from that index, according to the fund's mandate.

The index itself – the MSCI USA IMI – uses an "investable market" construction, which means it aims to capture companies across large, mid and small market capitalisations rather than focusing solely on the largest names.

8. ARK Genomic Revolution ETF ($ARKG)

ARKG 1-year price chart: up 39.7%, from US$27.21 to US$38.00. Range US$24.82 to US$56.77.

Price: US$38.00 · Daily: -5.6% · AUM: US$1.72B · MER: 0.75%

ARK Genomic Revolution ETF ($ARKG) is an actively managed fund, with a portfolio team selecting holdings rather than the fund following a fixed index. The mandate centres on genomics and life sciences, and according to that mandate, $ARKG seeks long-term capital growth through equity securities across multiple sectors – including healthcare, information technology, materials, energy and consumer discretionary.

Those holdings can come from both domestic and foreign markets, reflecting where the manager sees relevant companies operating across the genomic revolution theme.

9. VanEck Pharmaceutical ETF ($PPH)

PPH 1-year price chart: up 16.9%, from US$98.28 to US$114.85. Range US$97.57 to US$122.65.

Price: US$114.85 · Daily: -0.09% · AUM: US$1.02B · MER: 0.35%

VanEck Pharmaceutical ETF ($PPH) is built around a focused slice of the pharmaceutical industry. It aims to replicate the price and yield performance of the MVIS US Listed Pharmaceutical 25 Index, which tracks 25 U.S.-listed pharmaceutical companies.

With only 25 holdings, the index is deliberately concentrated. That means the fund's performance is closely tied to a relatively small group of companies rather than spread across a broader healthcare universe. The fund normally invests at least 80% of its assets in index securities, according to the fund's mandate.

10. Invesco S&P 500 Eql Wght Health Care ETF ($RSPH)

RSPH 1-year price chart: up 26.4%, from US$30.65 to US$38.75. Range US$29.59 to US$41.56.

Price: US$38.75 · Daily: -0.9% · AUM: US$1.21B · MER: 0.40%

Invesco S&P 500 Eql Wght Health Care ETF ($RSPH) is designed to track the S&P 500 Equal Weight Health Care Index, which covers the healthcare companies in the S&P 500 but assigns each roughly the same allocation. That construction is what sets $RSPH apart from market-capitalisation-weighted approaches, where the biggest companies pull the most weight.

In a standard market-cap fund, a handful of large pharmaceutical or managed-care companies can dominate performance. Here, a mid-sized medical device maker or specialty pharmaceutical firm carries a similar share of the portfolio to a much larger peer. The fund aims to invest at least 90% of its total assets in the securities that make up the index, in proportion to their index weightings.

➡️ Top 6 ARK ETFs to watch in 2026→

Common questions

How do I invest in US healthcare ETFs in Australia?

Every fund in this list trades on U.S. exchanges, so you'll need a share trading platform that provides access to U.S. markets. You search the ticker and place an order the same way you would for any other U.S.-listed stock. The funds in this list vary considerably in focus – from broad sector coverage to concentrated biotech, pharma or genomics mandates – so each fund's underlying index or mandate shapes what the portfolio actually holds.

What are the key risks of US healthcare ETFs?

Some of the key risks include regulatory decisions – approvals or rejections by health authorities can move company share prices sharply, and that effect is more pronounced in funds concentrated in biotechnology or pharmaceuticals. Research risk is closely related: companies working on clinical-stage products can see significant value swings around trial results. Because all funds in this list are priced in USD, movements in the AUD/USD rate affect what those holdings are worth in Australian dollars. Concentration is a further consideration – a fund tracking 25 pharmaceutical companies carries a different risk profile than one spread across the full healthcare sector.

How do broad healthcare ETFs differ from biotech, pharma and actively managed funds in this list?

Broad healthcare ETFs track the full sector – pharmaceuticals, medical devices, managed care, diagnostics and biotechnology together – rather than concentrating on one part of it. Biotech-focused funds hold companies working on biological medicines and related research, which means heavier exposure to clinical-trial and regulatory outcomes than a diversified sector fund would carry. Pharmaceutical funds narrow further still, following a defined list of drug companies. The one actively managed fund in this list, $ARKG, doesn't follow a fixed index at all; its portfolio team selects holdings based on a genomics and life sciences theme, so its composition can shift in ways an index fund's wouldn't.

How do management fees compare across healthcare ETFs?

The MERs in this list run from 0.08% to 0.75%. The cheapest funds – $XLV and $FHLC, both passive index trackers – charge 0.08%, with $VHT close behind at 0.09%. $ARKG, the only actively managed fund in this list, charges 0.75%. The remaining passive funds range from 0.35% (at $XBI and $PPH) up to 0.44% (at $IBB).

Disclaimer

Past performance is not a reliable indicator of future performance. When you invest, your capital is at risk. You should consider your own investment objectives, financial situation, and particular needs before making an investment decision. The value of your investments can go down as well as up and you may receive back less than your original investment. As always, do your own research and consider seeking appropriate financial advice before investing.

This is not personal financial advice nor a recommendation to invest in the securities listed. Any advice provided by Stake is of general nature only and does not take into account your specific circumstances. Trading and volume data from the Stake investing platform is for reference purposes only, the investment choices of others may not be appropriate for your needs and is not a reliable indicator of performance.

Please refer to hellostake.com/pricing for the fees that apply. When you trade securities priced in another currency, currency conversion fees may apply and movements in the exchange rate may affect your returns.


Portrait photo of Stake Desk, The freshest market insights at Stake.

Stake Desk

The freshest market insights

This article combines AI and human review from our analysts to bring you accurate, informative investing content at speed. For questions or suggestions, contact stakedesk@stake.com.au.


Subscribe

By subscribing, you agree to our Privacy Policy.

Explore Stake


Made in Australia

Sydney, Australia


Get the app

Scan QR code to download the app

Stakeshop Pty Ltd, trading as Stake, ACN 610 105 505, is an authorised representative (Authorised Representative No. 1241398) of Stakeshop AFSL Pty Ltd (Australian Financial Services Licence no. 548196). Stake SMSF Pty Ltd ACN 648 283 532 (‘Stake Super’) is not licensed to provide financial product advice under the Corporations Act. This specifically applies to any financial products which are established if you instruct Stake Super to set up a self managed super fund (‘SMSF’). When you sign up to Stake Super, you are contracting with Stake SMSF Pty Ltd who will assist in the establishment of a SMSF under a ‘no advice model’. You will also be referred to Stakeshop Pty Ltd to enable your trading account and bank account to be set up in order to use the Stake Website and/or App. For more information about SMSFs, see our SMSF Risks page. The Stake Accumulate Fund (ARSN 680 653 374) is issued by K2 Asset Management Ltd (ABN 95 085 445 094 AFSL 244 393), a wholly owned subsidiary of K2 Asset Management Holdings Ltd (ABN 59 124 636 782). The information on our website or our mobile application is not intended to be an inducement, offer or solicitation to anyone in any jurisdiction in which Stake is not regulated or able to market its services. At Stake and Stake Super, we’re focused on giving you a better investing experience but we don’t take into account your personal objectives, circumstances or financial needs. Any advice given by Stake is of a general nature only. As investments carry risk, before making any investment decision, please consider if it’s right for you and seek appropriate taxation and legal advice. Please view our Financial Services Guide, Terms & Conditions, Privacy Policy and Disclaimers before deciding to invest on or use Stake or Stake Super. By using our website or service in any way, you agree to our Privacy Policy and Terms & Conditions. All financial products involve risk and you should ensure you understand the risks involved as certain financial products may not be suitable to everyone. Past performance of any product described on this website is not a reliable indication of future performance. Stake and Stake Super are registered trademarks in Australia.

This information is being provided in connection with the Australian retail offer component of the initial public offering of shares of Class A common stock (“Shares”) in Anthropic, PBC (“Anthropic”) (“IPO”). The Australian retail offer is an offer of newly issued Shares by Anthropic (“Australian Retail Offer”) made under the Australian prospectus lodged with the Australian Securities and Investments Commission on 11 November 2026 (“Australian Prospectus”). This information does not form part of the Australian Prospectus, and anyone considering applying for Shares under the Australian Retail Offer should rely only on information in the Australian Prospectus and any supplementary or replacement Australian Prospectus. A copy of the Australian Prospectus is available on ipo.anthropic.com. Further information about Anthropic, the IPO, the Shares and the risks of investing in Anthropic is set out in the Australian Prospectus. Anyone considering applying for Shares under the Australian Retail Offer should read and consider the Australian Prospectus in full in deciding whether to acquire Shares under the Australian Retail Offer. Anyone who wants to acquire Shares under the Australian Retail Offer will need to complete the application form that accompanies the Australian Prospectus, in accordance with the process set out in the Australian Prospectus and any other instructions from their broker. Anthropic has applied to list its Class A common stock on the Nasdaq Global Select Market under the symbol “ANT”. Anthropic will not be applying for listing on the Australian Securities Exchange.

Us securities law disclaimer

A registration statement relating to these securities has been filed with the U.S. Securities and Exchange Commission (“SEC”) but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This communication does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. No offer to buy the securities can be accepted and no part of the purchase price can be received until the registration statement has become effective, and any such offer may be withdrawn or revoked, without obligation or commitment of any kind, at any time prior to its acceptance after the effective date. The prospectus in the registration statement and other documents Anthropic has filed with the SEC include additional information about Anthropic and the offering. Investors may get these documents for free by visiting EDGAR on the SEC’s website at www.sec.gov. The registration statement (including the US prospectus) is available at www.sec.gov

Copyright © 2026 Stake. All rights reserved.